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Introduction 
It is well known that the vast range of possible clinical 
manifestations of anthracycline cardiotoxicity includes serious 
arrhythmic events. 
Several studies have shown how, even after a brief period of 
anthracycline treatment, significant increases in indexes of 
ventricular recovery time (QT, QTc, JT, JTc) may occur, which, 
in the absence of any other pathologic ECG findings, may 
represent early markers of further arrhythmias related to 
cardiotoxicity. 
Torsade-de-pointes  (TdP)  is a life-threatening form of 
ventricular tachycardia and is a possible consequence of the 
long QT syndrome (LQTS). TdP rarely presents in the idiopathic 
form, but more commonly in the acquired form [1,2,3]. 
Pathological QTc prolongation is the most important sign 
frequently observed prior to the onset of TdP, even though there 
is high intra-individual and inter-individual variability.
Changes in electrolyte balance, i.e. hypokalaemia, 
hypocalcaemia and hypomagnesiemia, in addition to changes in 
hepatic and renal function, represent risk factors for TdP [4,5,6]. 
A wide range of chemotherapy agents have been associated 
with cardiotoxicity. The anthracyclines and related compounds 
are the most frequently implicated agents and can sometimes 
cause fatal cardiac arrhythmias. Individuals undergoing 
chemotherapy therefore require close cardiological follow-up not 
only during the cycles of the therapy but also at the end of it, 
especially those who are treated for protracted periods of time. 
 
Case report 
A 54-year-old male with progressive micro-molecular multiple 
myeloma, diagnosed in August 1999 (Durie and Salmon stage 
IIIA: medullary infiltration 95%) with diffuse bone distribution of 
the disease (sternocostal, clavicular, right femoral and 
vertebral), underwent three cycles (1999) of vincristine, 
adriamycin and dexamethasone (VAD) and subsequently high-
dose idarubicin (2000). 
The cumulative antracycline dose received by the patient at the 
time of event was: adriamycin 234 mg and idarubicin 75 mg. 
The patient had no clinical history of significant cardiac 
pathology and symptoms. 
The last echocardiogram performed after completion of 
chemotherapy in December 2000 showed a very slight increase 
in the dimensions and volume of the left ventricle with normal 
segmentary and global kinesis (EF 55%).
The patient was admitted as an emergency on 23 January 2002 
in a bad general clinical condition due to clear abdominal 
progression of the haemato-oncological disease. He underwent 
cyclic VAD chemotherapy, which resulted in a good clinical 
response.
The electrocardiogram (ECG) performed at admission was 
normal and showed a QT of 300 ms with QTc of 401 m (HR was 
110 bpm). 
During the night of 12 February 2002, a syncopal episode was 
observed. 
The ECG, performed immediately after the event, while showing 
no significant arrhythmias, showed a significant increase in 
intervals (QT 450, QTc 554 ms) 
The blood tests indicated a clinical picture of anaemisation (Hb: 
8.9 g/dl), hypokaliemia (3.23 mEq/l), hypocalcaemia (7.1 mg/dl) 
not corrected by albumin level (4.0 g/dl) and normal magnesium 
blood levels (1.89 mg/dl). 
Dynamic Holter monitoring performed the following morning, 
showed numerous episodes of non-sustained ventricular 
tachycardia of TdP type (Figures 1 and 2).
It was therefore decided to suspend the planned second cycle 
of VAD and to rapidly restore electrolytic balance, resolving the 
ventricular arrhythmia.
The patient was then, according to relatives, discharged. 
He died at home due to the progression of the haemato-
oncological disease. 
 
Discussion 
Anthracycline chemotherapy, which represents the treatment of 
choice for many haematologic and metastatic cancers, 
unfortunately carries with it the possibility of both early 
cardiotoxic phenomena, occurring during chemotherapy and 
also late cardiotoxic manifestations, occurring even months or 
years from the completion of treatment. 
Risk factors for the development of cardiotoxicity include: 
female sex, a cumulative AC dose greater than 550 mg/m
2, co-
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Figure 1: Non-sustained ventricular tachycardia of TdP-type during ECG Holter dynamic monitoring. 
 
 
Figure 2: Non-sustained ventricular tachycardia of TdP-type during ECG Holter dynamic monitoring.
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morbidities such as arterial hypertension and pre-existing 
cardiac diseases, and previous mediastinal radiation therapy 
[7]. 
The clinical manifestations of early cardiotoxicity commonly 
include: ventricular premature beats, supraventricular 
tachycardia, cardiomyopathy and sudden death [8]. 
The late form is generally characterized by heart failure, arising 
from left ventricular systo-diastolic dysfunction.
Recent studies have demonstrated the mode of onset of fatal 
arrhythmic events, even those which occur long after the 
completion of anthracycline treatment and emphasize the
consequent importance of long and careful follow-up in these 
patients [9]. 
Our study confirms the data in the literature, re-emphasizing the 
necessity for close cardiac monitoring of patients, undergoing 
anthracycline therapy. Such monitoring should comprise not 
only echocardiographic monitoring for left ventricular systo-
diastolic dysfunction, but also electrocardiographic monitoring 
(QTc) in order to exclude electrophysiological changes possibly 
related to life-threatening arrhythmias [10].
At the same time, it is of prime importance to prevent or correct 
immediately any electrolyte imbalances, above all hypokaliemia 
and  hypocalcaemia, which together represent a strong 
predisposing factor for the onset of severe and potentially fatal 
ventricular arrhythmias.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4  www.ecancermedicalscience.com 
C
a
s
e
 
R
e
p
o
r
t
secancer 2009, 3:147 
 
References 
1.  De Ponti F, Poluzzi E et al (2000) Q-T interval 
prolongation by non-cardiac drugs: lessons to be 
learned from recent experience Eur J Clin Pharmacol 56 
1–18 PMID: 10853872 doi: 10.1007/s002280050714 
2.  Roden DM, Lazzara R et al (1996) Multiple mechanisms 
in the long-QT syndrome. Current knowledge, gaps, 
and future directions  Circulation  94  1996–2012  PMID: 
8873679 
3.  Viskin S (1999) Long QT syndromes and torsade de 
pointes  Lancet  354  1625–33  PMID: 10560690  doi:  
10.1016/S0140-6736(99)02107-8 
4.  Ebert SN, Liu XK et al (1998) Female gender as a risk 
factor for drug-induced cardiac arrhythmias:evaluation 
of clinical and experimental evidence J Womens Health 
7 547–57 PMID: 9650155 doi: 10.1089/jwh.1998.7.547 
5.  Moss AJ (1999) The QT interval and torsade de pointes 
Drug Saf 2  Suppl 1 5–10 doi:10.2165/00002018-
199921001-00002 
6.  Murakawa Y, Yamashita T et al (1998) Ostensible day-
night difference of QT prolongation during long-term 
treatment with antiarrhythmic drugs: reappraisal of the 
law of ‘regression to the mean’ J Cardiovasc Pharmacol 
32  62–5  PMID: 9676722  doi: 10.1097/00005344-
199807000-00010 
7.  Isner JM et al (1983) Clinical et morphologic cardiac 
findings after anthracycline chemotherapy Am J Cardiol 
51  1167–74  PMID: 6573121  doi: 10.1016/0002-9149(83) 
90364-8 
8.  Hequet O, Le QH, Moullet I et al (2004) Subclinical late 
cardiomyopathy after doxorubicin therapy for 
lymphoma in adults  J Clin Oncol 22  1864–71  PMID: 
15143078 doi: 10.1200/JCO.2004.06.033 
9.  Arbel Y, Swartzon M and Justo D (2007) QT prolongation 
and Torsades de Pointes in patients previously treated 
with Anthracyclines Anti-Cancer Drugs 18 493–8 PMID: 
17351403 doi:  10.1097/CAD.0b013e328012d023 
10.  Sarubbi B, Orditura M, Ducceschi V et al (1997) 
Ventricular repolarization time indexes following 
anthracycline treatment  Heart vessels 12  262–6  PMID: 
9860192 doi: 10.1007/BF02766801  
 5  www.ecancermedicalscience.com 
C
a
s
e
 
R
e
p
o
r
t
s